Clarivate PLC

Clarivate PLC(CLVT)の株式分析

$1.610

+0.010 (+0.63%)終値時点

Loading chart…
高値
1.610
始値
1.560
出来高加重平均価格
1.59
出来高
2.85M
時価総額
3.81B
安値
1.540
売買代金
4.52M
EV/EBITDA(TTM)
5.79

Clarivate Plc is a provider of transformative intelligence. The Company offers intelligence solutions, workflow solutions, and tech-enabled services to its customers. Its Intelligence solutions include up-to-date knowledge assets, combining data, structured taxonomies, and analytical models that transform complex information into actionable insights powered by a combination of artificial intelligence (AI)-enabled software and human expertise. It operates through two segments, which include Academia & Government (A&G), and Intellectual Property (IP). The Academia & Government segment connects trusted content, responsible technology, and editorial expertise to fuel academic success and advance national outcomes for institutions and users globally. The Intellectual Property segment provides intellectual property data, software, and helps companies drive innovation, law firms achieve practice excellence, and organizations manage and protect critical intellectual property assets.

clarivate.com

AI分析 of Clarivate PLC (CLVT)

買い

Clarivate PLC (CLVT) is a good buy right now due to its recent strategic sale of the Life Sciences & Healthcare segment for $600 million, which is expected to enhance its focus and profitability. The current price of $1.61 is significantly below the analyst price target of $5 from Stifel, indicating a potential upside of over 200%. Additionally, the stock has shown a positive 5-day change of +8.78%, suggesting a recent upward momentum. However, the main risk is the company's substantial net loss of $268.6 million in Q2 2026, which reflects ongoing profitability challenges.

バリュエーション指標

Clarivate PLC(CLVT)の現在の予想PERは2.56で、5年平均は10.22です。

予想PER

割安
5年平均 P/E
10.22
現在のP/E
2.56
割高
16.12
割安
4.31

予想EV/EBITDA

適正
5年平均 EV/EBITDA
16.14
現在のEV/EBITDA
5.79
割高
33.87
割安
-1.59

予想PSR

割安
5年平均 P/S
2.05
現在のP/S
0.51
割高
3.34
割安
0.77

Alphio AI による CLVT の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%CLVT

$5.42

シナリオ価格

基

基本

基本 · 50%CLVT

$4.71

シナリオ価格

弱

弱気

弱気 · 25%CLVT

$4.31

シナリオ価格

CLVT を保有するクジラ

L

Lingotto Investment Management LLP

+ を保有CLVT

+19.59%

3か月リターン

B

BW Gestao de Investimentos Ltda.

+ を保有CLVT

+3.37%

3か月リターン

A

Atairos Management, L.P.

+ を保有CLVT

-3.37%

3か月リターン

T

Timucuan Asset Management Inc

+ を保有CLVT

-7.51%

3か月リターン

イベントタイムライン

2026-07-29 (ET)

06:30:00

Clarivate Maintains FY26 Revenue Outlook at $2.3B to $2.42B

06:30:00

Clarivate Appoints Michael Easton as CFO

06:30:00

Clarivate Reports Q2 Revenue of $587.3M

2026-07-14 (ET)

05:30:00

Clarivate Selected to Modernize France's National Academic Library System

2026-07-06 (ET)

16:30:00

Major Averages Open Higher as Chip Stocks Rebound

ニュース

CLVT のよくある質問 — Alphio AI が回答

Clarivate Plc is a provider of transformative intelligence. The Company offers intelligence solutions, workflow solutions, and tech-enabled services to its customers. Its Intelligence solutions include up-to-date knowledge assets, combining data, structured taxonomies, and analytical models that transform complex information into actionable insights powered by a combination of artificial intelligence (AI)-enabled software and human expertise. It operates through two segments, which include Academia & Government (A&G), and Intellectual Property (IP). The Academia & Government segment connects trusted content, responsible technology, and editorial expertise to fuel academic success and advance national outcomes for institutions and users globally. The Intellectual Property segment provides intellectual property data, software, and helps companies drive innovation, law firms achieve practice excellence, and organizations manage and protect critical intellectual property assets. It operates in the Industrials sector (SERVICES-COMPUTER PROCESSING & DATA PREPARATION industry).

Clarivate PLC (CLVT) is a good buy right now due to its recent strategic sale of the Life Sciences & Healthcare segment for $600 million, which is expected to enhance its focus and profitability. The current price of $1.61 is significantly below the analyst price target of $5 from Stifel, indicating a potential upside of over 200%. Additionally, the stock has shown a positive 5-day change of +8.78%, suggesting a recent upward momentum. However, the main risk is the company's substantial net loss of $268.6 million in Q2 2026, which reflects ongoing profitability challenges.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める